Clinical trial · Interventional
A Study of the Use of Text Message Reminders to Take Palbociclib
Oral Self-Management of Palbociclib (Ibrance®) Using Mobile Technology
NCT04216576CI-TRIAL-00106576active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find out whether it is feasible (acceptable to participants) to use a smartphone app to send text message reminders to take palbociclib, and whether these reminders are effective at helping people remember to take palbociclib according to the treatment schedule.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OhMD APP | Other | — | UNRESOLVED |
| Paper Drug Diary | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard of Care
- description
- Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care
- interventionNames
- Other: Paper Drug Diary
- type
- EXPERIMENTAL
- label
- Standard of Care + Intervention
- description
- Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention
- interventionNames
- Other: OhMD APP
Primary outcomes (1)
- measure
- Accuracy rate of medication self-administration
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a breast cancer diagnosis who are initiating therapy on palbociclib (Ibrance) * \>/= 18 years of age * Able to speak, read and write English * Willingness and ability to send and receive text messages with intervention app * Own a mobile telephone "smartphone" with text messaging capabilities. Only iPhone or Android operating systems support OhMD Application * Criteria applicable for both Control and Intervention groups * Flip-phones do not support OhMD Application and thus ineligible to participate * Initiation palbociclib (Ibrance) for the first time, either as monotherapy or in conjunction with other medication such as Lstrozole (Femara) or Fulvestrant (Faslodex) Exclusion Criteria: * History of taking palbociclib (Ibrance) * Patients whose caregivers coordinate their health care
References
Publications (1)
- DERIVEDMazzella-Ebstein A, Barton-Burke M, Anthony V, White C, Zhang Z, Smith A, Robson M. Oral self-management of palbociclib using mobile technology: Findings from a nurse-led randomized controlled trial. Asia Pac J Oncol Nurs. 2024 Oct 15;11(12):100604. doi: 10.1016/j.apjon.2024.100604. eCollection 2024 Dec. PMID 39697813